Idarubicine
Child-Pugh Class B
Stanford UniversityPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Child-Pugh Class B cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltitrexed Stanford University | Phase 3 | BB |
Inno-206 Stanford University | Phase 3 | BB |
Eloxatin Stanford University | Phase 3 | BB |
Ethiodized Oil Stanford University | Phase 3 | B |
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →